- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 18, Issue 33, 2012
Current Pharmaceutical Design - Volume 18, Issue 33, 2012
Volume 18, Issue 33, 2012
-
-
The Role of Platelets in Athero-Thrombotic Events
Authors: Matthias K. Freynhofer, Veronika Bruno, Johann Wojta and Kurt HuberThe crucial role of platelets in primary hemostasis and repair of injured endothelium is well established, as is their role in atherothrombosis. No other single cell type is responsible for as much morbidity and mortality, since death from ischemic heart disease or stroke is by far the leading cause of death worldwide. There is no doubt that our understanding of atherothrombosis has guided current antithrombotic strategies t Read More
-
-
-
Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Authors: Raffaele De Caterina and Giulia RendaAspirin is an antiplatelet drug, inhibiting the cyclooxygenase activity of platelet prostaglandin H synthase-1 and almost complete suppressing platelet capacity to generate the prothrombotic and proatherogenic thromboxane A2. Antiplatelet therapy with aspirin reduces the risk of serious vascular events by about a quarter in patients who are at high risk because they already have occlusive vascular disease. However, the i Read More
-
-
-
Clinical Use of Clopidogrel
Authors: Nikolaus Sarafoff, Robert A. Byrne and Dirk SibbingIn patients with stable and unstable coronary disease and those undergoing coronary stenting, the activation of platelets plays a central role in the occurrence of major thrombotic events such as death, myocardial infarction and stent thrombosis. Antiplatelet therapy for primary and secondary prevention of thromboembolic events is a cornerstone for the management of these patients and for many years the cyclooxygenase-1 Read More
-
-
-
Development and Clinical use of Prasugrel and Ticagrelor
Authors: Shiraz Ahmad and Robert F. StoreyAnti-platelet agents have left an indelible impression in the management of a wide range of pathologies. From the earliest therapeutic agents such as aspirin, to the cutting edge agents still undergoing development, they have the capability to powerfully manipulate platelet biology, a central player in thrombosis. The use of these agents is still subject to a number of important limitations that two newer agents, prasugrel and ti Read More
-
-
-
Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
More LessStroke prevention is highly effective but underutilized in medical care. Lifestyle modification, in the form of diet, exercise, smoking cessation, antihypertensive therapy, close control of diabetes and hyperlipidemia, can prevent most strokes. Selected subgroups can benefit from carotid surgery or stenting, anticoagulation for atrial fibrillation, and antiplatelet therapy. Evidence for these approaches and alternative manag Read More
-
-
-
Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease
Authors: Jose Luis Ferreiro and Dominick J. AngiolilloPatients with diabetes mellitus (DM) have accelerated atherosclerosis, which explains their high risk of cardiovascular disease and atherothrombotic complications. Among the several factors contributing to the prothrombotic condition which characterize patients with DM, platelet hyperreactivity is of major relevance since platelets play a key role in the development of atherosclerosis and its atherothrombotic complications. A nu Read More
-
-
-
Pharmacogenetics of the Antiplatelet Effect of Aspirin
Authors: Morten Wurtz, Steen Dalby Kristensen, Anne-Mette Hvas and Erik Lerkevang GroveThe concept of “pharmacogenetics” addresses genetically determined variation in how individuals respond to drugs. Accordingly, specific genetic variants have been suggested as contributors to a reduced response to various antiplatelet drugs. Aspirin is a cornerstone in secondary cardiovascular prevention and has been thoroughly investigated. The efficacy of aspirin is well documented, although with considerable i Read More
-
-
-
Pharmacogenetics of Clopidogrel
Clopidogrel used in conjunction with aspirin has a central role in the treatment of patients with an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI). The pharmacokinetic and pharmacodynamic responses to this drug are highly variable leaving up to one third of patients with inadequate platelet inhibition or high on-treatment platelet reactivity (HPR), and subsequent incr Read More
-
-
-
Platelet Turnover in Atherothrombotic Disease
More LessPlatelets play a pivotal role in primary hemostasis where their rapid response to vascular injury prevents excessive bleeding. To accomplish this, platelets are enriched in membrane receptors and cytoplasmic enzymes with often redundant and self-amplifying functions leading to platelet activation, release into the bloodstream of hemostatically active compounds and culminating with thrombus formation. However, the sa Read More
-
-
-
Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Authors: Morten Wurtz and Erik Lerkevang GroveThe modern era of antiplatelet therapy was founded by large clinical trials demonstrating the benefit of aspirin and clopidogrel in the treatment and prevention of acute coronary syndromes. The concept of antiplatelet drug “resistance” emerged during the 1990s with studies revealing considerable residual platelet aggregation in some patients despite aspirin treatment. In the wake of these reports, larger studies establi Read More
-
-
-
Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Authors: Rikke Sorensen, Jonas B. Olesen, Mette Charlot and Gunnar H. GislasonAntithrombotic therapy is a cornerstone of treatment in patients with cardiovascular disease with bleeding being the most feared complication. This review describes the risk of bleeding related to different combinations of antithrombotic drugs used for cardiovascular disease: acute coronary syndrome (ACS), atrial fibrillation (AF), cerebrovascular (CVD) and peripheral arterial disease (PAD). Different risk assessment schemes Read More
-
-
-
Platelet Function Testing in Atherothrombotic Disease
Authors: Erik Lerkevang Grove, Robert F. Storey and Morten WurtzPlatelet function testing was introduced more than a century ago with the invention of bleeding time; a test which has now been replaced by more accurate methods. Light transmittance aggregometry is traditionally regarded as the gold standard for evaluating platelet function. However, lately the position of light transmittance aggregometry has been challenged by a panel of new instruments. Aspirin and P2Y12-inhibitors are a Read More
-
-
-
Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?
P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization. Multiple lines of evidence suggest that the level of on-treatment platelet reactivity inhibition with P2Y12 ADP receptor antagonists correlates with thrombotic recurrences. Recent studies observed a relationship between Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
